Study identifies antibody that alleviates symptoms in neuromyelitis optica in rats

January 18, 2018, Osaka University
Inhibition of RGMa ameliorates the severity of NMO model rats. Credit: Osaka University

Neuromyelitis optica (NMO), also known as Devic's disease, is a central nervous system disorder that primarily affects the eye nerves (optic neuritis) and the spinal cord (myelitis). It occurs when the body's immune system produces autoantibody in the central nervous system. Autoantibodies are antibodies that target one or more of the individual's own proteins. Most patients with NMO present severe clinical symptoms, such as blindness in one or both eyes, weakness or paralysis in the legs or arms, and painful spasms.

At present, there is no cure for NMO, and no medications have been specifically approved to treat it. This critical gap has motivated a team of researchers from Osaka University to discover new therapeutics against NMO.

"Recently, a role for the protein repulsive guidance molecule-a (RGMa) in the immune system has become apparent. Inhibiting RGMa with its antibody in multiple sclerosis (MS) in rats promotes motor recovery after injury and improve disease scores," explains Kana Harada, lead author of the team's study recently published in Scientific Reports. "Because NMO and MS are both immune-mediated neurodegenerative diseases with broadly comparable symptoms, we hypothesized that anti-RGMa antibody may have a suppressive effect on NMO."

The team started off by developing a new rat model that mimics the pathology of intractable NMO by the injection of the antibody NMO-immunoglobulin G (IgG) into the spinal cord. NMO is characterized by the presence of the serum autoantibody NMO-IgG. In contrast to previous animal models of NMO that generally produced disseminated lesions, the new localized model has a single well-demarcated inflammatory lesion, allowing precise investigation of the correlation between the lesion with the deficit in motor function disrupting the corticospinal tract.

Study identifies antibody that alleviates symptoms in neuromyelitis optica in rats
Fig.2. Anti-RGMa mAb partially restored AQP4 and GFAP expression in NMO model rats. Credit: Osaka University

"We are excited to find in rats that developed , relaxation of neurological symptoms was observed by suppressing RGMa using humanized monoclonal anti-RGMa antibody ," corresponding author Yuki Fujita says. "Also, the inhibition of RGMa promotes restoration of injured neural networks, presumably leading to a delay in the progression of the secondary phase of NMO."

"Our findings support the potential of humanized anti-RGMa antibody as a valid therapeutic approach. We expect this antibody to be further explored as a new therapeutic agent NMO," co-author Toshihide Yamashita notes.

Study identifies antibody that alleviates symptoms in neuromyelitis optica in rats
Fig.3. RGMa inhibition attenuates neuronal damage in NMO model rats. Credit: Osaka University

Explore further: Team develops neuro test that distinguishes demyelinating diseases from multiple sclerosis

More information: Kana Harada et al. Inhibition of RGMa alleviates symptoms in a rat model of neuromyelitis optica, Scientific Reports (2018). DOI: 10.1038/s41598-017-18362-2

Related Stories

Team develops neuro test that distinguishes demyelinating diseases from multiple sclerosis

November 28, 2017
Mayo Clinic has launched a first-in-the-U.S. clinical test that will help patients who recently have been diagnosed with an inflammatory demyelinating disease (IDD) but may be unsure of the exact disorder. Neurologic-related ...

An antibody-based drug for multiple sclerosis

July 20, 2016
Inserm Unit U919, directed by Prof. Denis Vivien ("Serine Proteases and Physiopathology of the Neurovascular Unit") has developed an antibody with potential therapeutic effects against multiple sclerosis. The study, directed ...

Researchers identify biomarker to speed diagnosis in brain and spinal cord inflammation

November 14, 2016
Research from Mayo Clinic included in the November issue of JAMA Neurology identifies a new biomarker for brain and spinal cord inflammation, allowing for faster diagnosis and treatment of patients.

Miami project presents data demonstrating therapeutic potential of SRK-015 in SCI

July 10, 2017
The Miami Project to Cure Paralysis, a Center of Excellence at the University of Miami Miller School of Medicine, in collaboration with Scholar Rock, a biotechnology company focused on discovering and developing drugs that ...

Most patients with unknown spinal cord disease later given specific diagnosis, study shows

January 9, 2018
A study by Mayo Clinic researchers found that most patients with suspected spinal cord inflammation of unknown cause have an alternative, specific diagnosis. The research is published in Neurology, the medical journal of ...

Recommended for you

Brain activity linked to stress changes chemical codes

April 24, 2018
Five years ago, a team of University of California San Diego neurobiologists published surprising findings describing how rats' brain cells adopted new chemical codes when subjected to significant changes in natural light ...

Scientists develop new method that uses light to manage neuropathic pain in mice

April 24, 2018
For patients with neuropathic pain, a chronic condition affecting 7 to 8 percent of the European population, extreme pain and sensitivity are a daily reality. There is currently no effective treatment. Scientists from EMBL ...

Animal cyborg—behavioral control by activating 'toy craving' circuit

April 24, 2018
Children love to get toys from parents as presents. This craving for objects also underlies object hoarding disorders and shopping addiction. However, the biological causes of object pursuit have remained unknown. Part of ...

Imagined and actual movements are controlled by the brain in the same way

April 24, 2018
A new study from Karolinska Institutet in Sweden shows that imagined movements can change our perception in the same way as real, executed movements do. The research, which is presented in the scientific journal Nature Communications, ...

Heading—not collisions—cognitively impairs players

April 24, 2018
Worse cognitive function in soccer players stems mainly from frequent ball heading rather than unintentional head impacts due to collisions, researchers at Albert Einstein College of Medicine have found. The findings suggest ...

In Huntington's disease, heart problems reflect broader effects of abnormal protein

April 24, 2018
Researchers investigating a key signaling protein in Huntington's disease describe deleterious effects on heart function, going beyond the disease's devastating neurological impact. By adjusting protein levels affecting an ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.